{"id":"semaglutide-pen-injector","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Nausea"},{"rate":"10-15","effect":"Vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Constipation"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"5-15","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, delays gastric emptying to slow nutrient absorption, and acts on the central nervous system to reduce hunger and food intake. These combined effects result in improved glycemic control and significant weight loss.","oneSentence":"Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:19.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT07400107","phase":"PHASE3","title":"AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-05-20","conditions":"Obesity, Overweight, Diabetes Mellitus, Type 2","enrollment":1000},{"nctId":"NCT03811561","phase":"PHASE3","title":"A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-05-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1500},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT05819138","phase":"PHASE3","title":"Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-21","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT07282613","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-04","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT06852391","phase":"PHASE4","title":"JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-18","conditions":"Obesity (Disorder)","enrollment":74},{"nctId":"NCT07302802","phase":"","title":"Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice","status":"RECRUITING","sponsor":"Prof. Dr. Martin Wabitsch","startDate":"2025-12-01","conditions":"Monogenic Obesity","enrollment":70},{"nctId":"NCT06468748","phase":"PHASE4","title":"The Effects of Semaglutide on Body Composition and Performance in Military Personnel","status":"WITHDRAWN","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2024-08-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT05891587","phase":"PHASE2","title":"Semaglutide Therapy for Alcohol Reduction - Tulsa","status":"COMPLETED","sponsor":"Oklahoma State University Center for Health Sciences","startDate":"2023-07-07","conditions":"Alcohol Use Disorder","enrollment":80},{"nctId":"NCT07011667","phase":"PHASE3","title":"A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-03","conditions":"Obesity","enrollment":609},{"nctId":"NCT06797869","phase":"PHASE2","title":"A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-29","conditions":"Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","enrollment":142},{"nctId":"NCT06499857","phase":"PHASE3","title":"Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-04-14","conditions":"Overweight or Obesity, Atrial Fibrillation","enrollment":200},{"nctId":"NCT06716307","phase":"PHASE1","title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Obesity","enrollment":18},{"nctId":"NCT06548490","phase":"PHASE2","title":"GLP-1R Agonist Treatment for Opioid Use Disorder","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2025-01-13","conditions":"Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders","enrollment":200},{"nctId":"NCT06909006","phase":"PHASE3","title":"Semaglutide Treatment in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-10","conditions":"Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM)","enrollment":122},{"nctId":"NCT06908694","phase":"PHASE4","title":"Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-07-02","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT05424003","phase":"PHASE2","title":"Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2024-02-22","conditions":"NAFLD","enrollment":50},{"nctId":"NCT05071898","phase":"PHASE1","title":"Pharmacogenetics of Response to GLP1R Agonists","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2022-04-11","conditions":"Obesity, Diabetes Type 2","enrollment":600},{"nctId":"NCT05303857","phase":"PHASE4","title":"Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2022-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT05067621","phase":"PHASE2","title":"Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-07-17","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT06411210","phase":"PHASE2","title":"Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-07-16","conditions":"Diabetes type1, Obesity","enrollment":54},{"nctId":"NCT05302596","phase":"PHASE2","title":"Semaglutide Use in Elderly Obese Patients","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2022-09-01","conditions":"Obesity, Aging","enrollment":16},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT04979130","phase":"PHASE4","title":"Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-01-01","conditions":"Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability","enrollment":69},{"nctId":"NCT05746039","phase":"PHASE1, PHASE2","title":"Feasibility of Semaglutide in Advanced Lung Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-29","conditions":"Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease","enrollment":8},{"nctId":"NCT04873050","phase":"PHASE4","title":"Treatment to Regress to Normoglycemia in Women with a Recent History of GDM","status":"RECRUITING","sponsor":"Woman's","startDate":"2022-01-13","conditions":"Pre Diabetes, Postpartum Disorder","enrollment":102},{"nctId":"NCT06863363","phase":"PHASE4","title":"PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"","conditions":"Non-diabetic Obesity","enrollment":212},{"nctId":"NCT06619015","phase":"PHASE2, PHASE3","title":"Tailoring Obesity Treatment Trial","status":"SUSPENDED","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2025-09","conditions":"Obesity, Appetite Regulation, PreDiabetes","enrollment":40},{"nctId":"NCT05569772","phase":"PHASE3","title":"Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-09-14","conditions":"Glucose Intolerance After a Recent History of Gestational Diabetes","enrollment":252},{"nctId":"NCT04639414","phase":"PHASE4","title":"Combined Active Treatment in Type 2 Diabetes with NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Diabetes Center","startDate":"2021-03-26","conditions":"Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)","enrollment":192},{"nctId":"NCT04892199","phase":"PHASE4","title":"Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-09-01","conditions":"Metabolic Disturbance, Schizophrenia, Type 2 Diabetes","enrollment":104},{"nctId":"NCT06497049","phase":"PHASE1","title":"Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-06-30","conditions":"Pharmacokinetics, Safety Issues, Bioequivalence","enrollment":120},{"nctId":"NCT06449625","phase":"PHASE2","title":"Semaglutide in Auto-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Klaus Gottlob Müller","startDate":"2024-08-12","conditions":"Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity","enrollment":40},{"nctId":"NCT06149260","phase":"PHASE1","title":"Subcutaneous Semaglutide in Systemic Scleroderma","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-02-29","conditions":"Scleroderma, Systemic, Fibrosis, Semaglutide","enrollment":10},{"nctId":"NCT04741074","phase":"PHASE3","title":"Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy","status":"TERMINATED","sponsor":"Geisinger Clinic","startDate":"2021-07-23","conditions":"CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese","enrollment":15},{"nctId":"NCT05232708","phase":"PHASE1","title":"A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-01-19","conditions":"Healthy Volunteers (Diabetes Mellitus, Type 2)","enrollment":18},{"nctId":"NCT05153564","phase":"PHASE1","title":"A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-13","conditions":"Diabetes Mellitus, Type 2","enrollment":27},{"nctId":"NCT03985384","phase":"PHASE4","title":"Semaglutide Treatment On Coronary Progression","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2019-04-30","conditions":"Type 2 Diabetes, Coronary Artery Disease","enrollment":140},{"nctId":"NCT06005012","phase":"PHASE2","title":"Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM","status":"UNKNOWN","sponsor":"University of California, San Diego","startDate":"2023-07-25","conditions":"Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease","enrollment":120},{"nctId":"NCT05870462","phase":"PHASE4","title":"Semaglutide and Vascular Regeneration","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2023-04-29","conditions":"Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05950516","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-07-10","conditions":"Type 2 Diabetes","enrollment":478},{"nctId":"NCT05857085","phase":"PHASE4","title":"Novel Therapeutics and Endothelial Dysfunction in T1DM Patients","status":"COMPLETED","sponsor":"General and Teaching Hospital Celje","startDate":"2021-12-15","conditions":"Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers","enrollment":90},{"nctId":"NCT04083820","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-09-16","conditions":"Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT04261933","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-02-13","conditions":"Diabetes Mellitus, Type 2","enrollment":789},{"nctId":"NCT04094415","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-10-28","conditions":"Diabetes Mellitus, Type 2","enrollment":581},{"nctId":"NCT03929679","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":218},{"nctId":"NCT05606471","phase":"PHASE4","title":"Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2021-09-15","conditions":"Type 2 Diabetes Mellitus in Obese","enrollment":45},{"nctId":"NCT05249881","phase":"EARLY_PHASE1","title":"\"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan.\"","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2022-03-10","conditions":"Diabetes Mellitus, Type 2, Weight Change, Body","enrollment":300},{"nctId":"NCT03811574","phase":"PHASE3","title":"STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-21","conditions":"Overweight, Obesity","enrollment":401},{"nctId":"NCT04228354","phase":"PHASE1","title":"A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-29","conditions":"Healthy Volunteers, Overweight, Obesity","enrollment":28},{"nctId":"NCT03648281","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-08-24","conditions":"Diabetes Mellitus, Type 2","enrollment":333},{"nctId":"NCT04187300","phase":"PHASE1","title":"A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-12-16","conditions":"Overweight, Obesity","enrollment":68},{"nctId":"NCT04152915","phase":"PHASE1","title":"A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-11-25","conditions":"Healthy Volunteers, Diabetes Mellitus, Type 2","enrollment":68},{"nctId":"NCT04067999","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-08-05","conditions":"Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT03457012","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-03-29","conditions":"Diabetes Mellitus, Type 2","enrollment":462},{"nctId":"NCT03631186","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-09-12","conditions":"Diabetes Mellitus, Type 2","enrollment":215},{"nctId":"NCT03987074","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-07-29","conditions":"Nonalcoholic Steatohepatitis","enrollment":109},{"nctId":"NCT03876015","phase":"","title":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-01","conditions":"Diabetes Mellitus, Type 2","enrollment":215},{"nctId":"NCT04238962","phase":"PHASE1","title":"A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-02-03","conditions":"Overweight, Obesity","enrollment":111},{"nctId":"NCT03611322","phase":"PHASE1","title":"A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-08-08","conditions":"Diabetes Mellitus, Type 2","enrollment":54},{"nctId":"NCT03598621","phase":"PHASE1","title":"A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-07-23","conditions":"Diabetes Mellitus, Type 2","enrollment":68},{"nctId":"NCT04012255","phase":"PHASE1","title":"A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-15","conditions":"Overweight, Obesity","enrollment":29},{"nctId":"NCT04061200","phase":"PHASE4","title":"Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria","status":"UNKNOWN","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-11-01","conditions":"Type 2 Diabetes With Renal Manifestations","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ozempic","Wegovy®","Wegovy","Placebo Semaglutide 1mg","Placebo Ozempic"],"phase":"marketed","status":"active","brandName":"Semaglutide Pen Injector","genericName":"Semaglutide Pen Injector","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}